Comparative Pharmacology
Head-to-head clinical analysis: HC 1 versus LOCAMETZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 1 versus LOCAMETZ.
HC #1 vs LOCAMETZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown
Metformin hydrochloride is a biguanide antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes mellitus. It primarily decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
Locametz (gallium Ga 68 gozetotide) is administered intravenously at a dose of 3-5 mCi (110-185 MBq) as a single injection for PET imaging. No repeated dosing schedule is defined.
None Documented
None Documented
2–4 hours (terminal); prolonged in renal impairment.
Terminal elimination half-life of 14 hours (range 12-16 h); clinically, steady-state achieved after 3 days.
Renal: 90% as unchanged drug; fecal: 10%.
Primarily renal excretion (70% unchanged), with 20% fecal elimination via biliary secretion; 10% metabolized.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid